Immupharma PLC Appointment of Joint Brokers (1740B)
September 19 2018 - 2:01AM
UK Regulatory
TIDMIMM
RNS Number : 1740B
Immupharma PLC
19 September 2018
19 September 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
Appointment of Joint Brokers
ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and
development company, is pleased to announce that it has, with
immediate effect, appointed Stanford Capital Partners and SI
Capital as joint brokers. They will work in conjunction with
Northland Capital Partners who are the Company's NOMAD and
broker.
Commenting on the announcement, Tim McCarthy, Chairman of
ImmuPharma said:
"As per our recently announced corporate update, we are looking
forward with confidence to the future progress of ImmuPharma. As
part of our continued proactive investor relations strategy, we
also look forward to working with Stanford Capital and SI Capital
as part of our corporate advisory team."
For further information please contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.co.uk) 7152 4080
Tim McCarthy, Chairman
+ 44 (0) 7721
Lisa Baderoon, Head of Investor Relations 413496
Northland Capital Partners Limited (NOMAD & Joint +44 (0)20 3861
Broker) 6625
David Hignell, Dugald Carlean, Jamie Spotswood,
Corporate Finance
Rob Rees, Corporate Broking
Stanford Capital Partners (Joint Broker) +44 (0) 20
Patrick Claridge 3815 8880
Chris Coleman
SI Capital (Joint Broker) +44 (0) 1483
Nick Emerson 413500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPFKFDDABKDQCD
(END) Dow Jones Newswires
September 19, 2018 02:01 ET (06:01 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
